Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT NO-REFLOW
NCT05427786Phase 4Recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Dec 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nicorandil in coronary artery disease (CAD), no-reflow phenomenon, sponsored by Korea University Anam Hospital. Started Dec 2022; status: recruiting.
02
Drugs
nicorandil
03
Conditions
coronary artery disease (CAD)no-reflow phenomenon
Beyond the preview
Go deeper on NCT05427786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427786.